CD274 and hepatocellular carcinoma: Tremelimumab received a rare drug qualification for the treatment of HCC by the U. S. Food & Drug Administration (US FDA), although the development of CTLA-4 blockers for HCC led to the combined application of PD-1 and PD-L1 inhibitors.